- Immunization:
- Standard dosing: IM 1mL at 0, 1 and 6 months
- Accelerated dosing: IM 1mL on days 0, 7 and 21-30, followed by a 4th dose at 12 months
- Injection:
- 720 EU + 20mcg/mL
- Vaccine should be administered by intramuscular injection only as a 1-mL dose
- Administer in deltoid region
- Do NOT administer in gluteal region; such injections may result in a 30 suboptimal response
- Do NOT administer this product intravenously, intradermally or subcutaneously
- The vaccine should be re-suspended before use
- When re-suspended, the vaccine will have a uniform hazy white appearance
- Upon storage, a fine white deposit with a clear colorless layer above may be present
Inactivated HAV combined with purified HBsAg induce Ab production
Exact mechanism unknown of inducing antibody formation.
- Injection site reaction
- Headache
- Fatigue
- Diarrhea
- Nausea
- Fever
- URI
- Hypersensitivity to drug or ingredient
- Hypersensitivity to yeast
- Hypersensitivity to neomycin
- Belimumab
Drug Status
| Availability | Prescription only |
| Pregnancy | Use when benefits outweigh risks |
| Breastfeeding | Can be used |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Twinrix Adult | >720 EU + 20 mcg/mL | Injection | 1mL | GSK Ltd | GSK Ltd |
| Twinrix Junior | >720 EU + 20 mcg/mL | Injection | 0.5mL | GSK Ltd | GSK Ltd |